Holliday junction recognition protein as a prognostic biomarker and therapeutic target for oral cancer
Bayarbat Tsevegjav(Shiga University of Medical Science), Yataro Daigo(The University of Tokyo), Masanori Shinohara(Kumamoto University), Ming Zhu(AbbVie (United States)), Atsushi Takano(The University of Tokyo), Yoshihiro Yoshitake(Kumamoto University)
Cited by 11
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
HJURP Is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres
|Cell|2009|636
Mutations truncating the EP300 acetylase in human cancers
|Nature Genetics|2000|593